Logo
x

Search

Subscribe Now

Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active U...

  • October 15, 2021
Janssen Presents Three-Year Data of Stelara (ustekinumab) in P-lll UNIFI LTE Study for the Treatment of Moderately to Severely Active Ulcerative Colitis at ECCO

Janssen Presents Three-Year Data of Stelara (ustekinumab) in P-lll UNIFI LTE Study for the Treatment of Moderately to Severely Act...

  • July 12, 2021
BMS' Zeposia (ozanimod) Receives the US FDA's Approval for Ulcerative Colitis

BMS' Zeposia (ozanimod) Receives the US FDA's Approval for Ulcerative Colitis

  • May 28, 2021
Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

  • March 23, 2020
Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis

  • October 21, 2019
Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severely Active Ulcerative Colitis (UC)

Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severe...

  • January 9, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.